Quemliclustat - Arcus Biosciences
Alternative Names: AB-680; Small molecule CD73 inhibitor - Arcus BiosciencesLatest Information Update: 08 Nov 2024
Price :
$50 *
At a glance
- Originator Arcus Biosciences
- Developer Arcus Biosciences; Gilead Sciences; UCLAs Jonsson Comprehensive Cancer Center
- Class 2 ring heterocyclic compounds; Amines; Antineoplastics; Fluorobenzenes; Phosphonic acids; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action 5-nucleotidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Adenocarcinoma
- Phase II Cholangiocarcinoma; Non-small cell lung cancer
- Phase I/II Colorectal cancer
- No development reported Cancer
- Discontinued Prostate cancer
Most Recent Events
- 30 Nov 2024 Phase-III clinical trials in Adenocarcinoma (First-line therapy, Combination therapy, Metastatic disease) in USA (IV) (NCT06608927)
- 03 Oct 2024 Arcus Biosciences plans the phase III PRISM-1 trial in Adenocarcinoma (Metastatic disease, Combination therapy, First line therapy) (IV, Infusion) (NCT06608927) (EUCT2024-513317-12-00)
- 19 Sep 2024 Arcus Biosciences reinitiates a phase-I/II trial in Adenocarcinoma (Combination therapy, Late-stage disease, Inoperable/Unresectable, First-line therapy) and in Adenocarcinoma (Combination therapy, First-line therapy, Late-stage disease) in USA (IV) due to early accrual (NCT05688215)